Dr. David Devilbiss at Rowan University is researching treatments for cognitive impairments caused by traumatic brain injury (TBI).

A multi-site study has been awarded a $2.1 million grant from NCATS to evaluate the impact of remote versus in-person approaches to clinical trials.

The Citrin Foundation and University of Zürich have established the world's first center dedicated to translational research in urea cycle disorders with a CHF$10 million commitment over ten years.

Tryptamine Therapeutics and Swinburne University have signed an agreement to conduct the world's first clinical trial using intravenous psilocin (TRP-8803) to treat Binge Eating Disorder, with recruitment beginning this quarter.

A young boy named Peta, diagnosed with a rare tumor as an infant, received personalized medicine at the University Hospital Brno.

China Medical University (CMU) and Healthcare System secured 17 awards at the Taiwan National Innovation Awards, recognizing breakthroughs in biotechnology and smart healthcare.

Khyber Medical University (KMU) is set to begin clinical trials for a locally developed herbal medicine targeting cutaneous leishmaniasis (CL).

RedHill Biopharma and Duke University are collaborating to study opaganib as a countermeasure for phosgene inhalation injury.

TAE Life Sciences and Ohio State University have formed the first U.S.-based academic-industry alliance focused on developing novel boron-based drug compounds for Boron Neutron Capture Therapy (BNCT).

The University at Buffalo (UB) has inaugurated the FOXG1 Research Center (FRC) to focus on developing treatments for FOXG1 syndrome and related neurodevelopmental disorders.

Katherine Hegedorn is the first patient in Northeast Ohio to receive Tzield, an FDA-approved drug that delays the onset of Type 1 diabetes and the need for insulin.

Researchers at Ulster University have identified protein markers in senescent cells for earlier diagnosis and more effective treatment of Chronic Kidney Disease (CKD).

The FDA has awarded funding to the University of Rochester Medical Center (URMC) to develop digital measures for Huntington's disease.

Sentynl Therapeutics has published the first comprehensive clinical evidence for NULIBRY (fosdenopterin), showing statistically significant survival benefits in patients with Molybdenum Cofactor Deficiency Type A compared to untreated patients.

The ACURATE IDE trial showed that the Acurate neo2 TAVI valve did not meet noninferiority criteria compared to commercially available valves for severe aortic stenosis.

The University of Washington has announced the finalization of the Diversity in Clinical Trials Guidance and the implementation of a Revised Short Form Consent Policy, effective from January 1, 2026. These changes aim to improve participation from underrepresented communities in clinical trials and streamline the consent process for non-English speaking participants.

The article discusses the long-term efficacy and safety of iptacopan, a treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with anaemia, as presented by Prof. Antonio Risitano from the University of Naples, Italy.

A recent clinical trial by Soroka University Medical Center and Cannbit-Tikun Olam shows significant positive effects of medical cannabis on PTSD patients, with many reducing their use of other medications and reporting improved quality of life.

QIAGEN is advancing plans to introduce three new automated sample preparation instruments between 2025-2026, designed to enhance laboratory efficiency and sustainability across different throughput needs.

Washington University School of Medicine's 20-year clinical trial development program has successfully trained 118 oncology fellows, with 79% achieving institutional review board approval for their trials.